| __timestamp | Ionis Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 17986000 |
| Thursday, January 1, 2015 | 37173000 | 32480000 |
| Friday, January 1, 2016 | 48616000 | 68081000 |
| Sunday, January 1, 2017 | 108488000 | 169906000 |
| Monday, January 1, 2018 | 244622000 | 248932000 |
| Tuesday, January 1, 2019 | 287000000 | 354100000 |
| Wednesday, January 1, 2020 | 354000000 | 433300000 |
| Friday, January 1, 2021 | 186000000 | 583300000 |
| Saturday, January 1, 2022 | 151000000 | 752700000 |
| Sunday, January 1, 2023 | 232600000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry leaders: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals, Inc., from 2014 to 2023.
Neurocrine Biosciences has shown a remarkable increase in SG&A expenses, growing by nearly 500% over the decade. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Ionis Pharmaceuticals experienced a more modest increase of around 100%, indicating a more conservative approach to operational spending.
By 2023, Neurocrine's SG&A expenses were approximately 3.8 times higher than Ionis's, highlighting their divergent strategies. This data provides a fascinating glimpse into how these companies allocate resources to maintain their competitive edge in the biotech sector.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.